PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17409429-3 2007 We found that PD98059, which itself has minimal apoptogenic activity, acts synergistically with Nutlin-3a to induce apoptosis in wild-type p53 AML cell lines OCI-AML-3 and MOLM-13. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 14-21 tumor protein p53 Homo sapiens 139-142 18406507-10 2008 SB203580 and PD98059, specific inhibitors of p38 MAPK and ERK, respectively, suppressed phosphorylation of p53 at Ser15, but the accumulation of p53 was only moderately reduced. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 13-20 tumor protein p53 Homo sapiens 107-110 18406507-10 2008 SB203580 and PD98059, specific inhibitors of p38 MAPK and ERK, respectively, suppressed phosphorylation of p53 at Ser15, but the accumulation of p53 was only moderately reduced. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 13-20 tumor protein p53 Homo sapiens 145-148 17409429-4 2007 Interestingly, PD98059 enhanced nuclear proapototic function of p53 in these cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 15-22 tumor protein p53 Homo sapiens 64-67 17409429-5 2007 In accordance with the activation of transcription-dependent apoptosis, PD98059 treatment promoted the translocation of p53 from the cytoplasm to the nucleus in OCI-AML-3 cells, in which p53 primarily initiates transcription-independent apoptosis when cells are treated with Nutlin-3a alone. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 72-79 tumor protein p53 Homo sapiens 120-123 17409429-5 2007 In accordance with the activation of transcription-dependent apoptosis, PD98059 treatment promoted the translocation of p53 from the cytoplasm to the nucleus in OCI-AML-3 cells, in which p53 primarily initiates transcription-independent apoptosis when cells are treated with Nutlin-3a alone. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 72-79 tumor protein p53 Homo sapiens 187-190 17409429-7 2007 PD98059 prevented p53-mediated induction of p21 at the transcriptional level. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor protein p53 Homo sapiens 18-21 17409429-8 2007 The repressed expression of antiapototic p21 also seemed to contribute to synergism between PD98059 and Nutlin-3a because (a) the synergistic apoptogenic effect was preserved in G(1) cells, (b) p53-mediated induction of p21 was preferentially seen in G(1) cells, (c) PD98059 strongly antagonized p21 induction by Nutlin-3a, and (d) cells with high p21 levels were resistant to apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 92-99 tumor protein p53 Homo sapiens 194-197 16928824-6 2006 The interaction of COX-2, p53, and p300, as well as resveratrol-induced apoptosis, was inhibited by a MAPK activation inhibitor, PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 129-136 tumor protein p53 Homo sapiens 26-29 16840547-11 2006 PD98059 inhibited this delayed activation of ERK and effects of S179D PRL on all measures except p53 levels or activity of the Bax promoter. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 0-7 tumor protein p53 Homo sapiens 97-100 16880619-7 2006 The phoshatidylinositol 3-kinase (PI3-K) family inhibitor wortmanin and the MEK inhibitor (PD98059) rescued the viability loss induced by uncarinic acid E through the expression of p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 91-98 tumor protein p53 Homo sapiens 181-184 15880691-6 2005 Furthermore, inhibition of ERK through addition of PD98059 stimulated p53 activation in MCF7 cells and also led to upregulation of p53 downstream targets, p21 and Bax, which is a proapototic member of Bcl-2 family triggering mitochondrial pore opening. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 51-58 tumor protein p53 Homo sapiens 70-73 16814113-9 2006 The effects of RSVL on ERKs and on p53 phosphorylation were abrogated by either the MAPK inhibitor PD98059 or the p53 inhibitor pifithrine-alpha. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 99-106 tumor protein p53 Homo sapiens 35-38 16527552-10 2006 Both Wortmannin and PD98059 elevated the level of p53 expression strikingly, however, only PD98059 suppressed the up-regulation trend of c-Myc expression induced by etoposide. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 20-27 tumor protein p53 Homo sapiens 50-53 16180010-6 2006 In contrast, a specific inhibitor of ERK kinase (U0126 or PD98059) could abolish the accumulation as well as the phosphorylation of p53 at Ser15. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 58-65 tumor protein p53 Homo sapiens 132-135 15880691-6 2005 Furthermore, inhibition of ERK through addition of PD98059 stimulated p53 activation in MCF7 cells and also led to upregulation of p53 downstream targets, p21 and Bax, which is a proapototic member of Bcl-2 family triggering mitochondrial pore opening. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 51-58 tumor protein p53 Homo sapiens 131-134 15899123-9 2005 Phosphorylation of ERK resulted in up-regulation of p53 expression, which was blocked by mitogen-activated protein kinase (MEK), inhibitor PD 98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 139-147 tumor protein p53 Homo sapiens 52-55 14511359-13 2003 Inhibited the activation of p42/p44 mitogen-activated protein kinase (MAPK) by PD98059, a specific inhibitor of extracellular regulatory kinase (ERK), significantly decreased cell viability and enhanced the expression of p53 induced by ASA. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 79-86 tumor protein p53 Homo sapiens 221-224 15179185-4 2004 The effect on p53 was not a direct result of inhibition of extracellular signal-regulated kinase-1/2 (ERK1/2) activation by TSA, as treatment of the cells with the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEK1) inhibitor PD98059 did not result in decreased p53 protein level. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 261-268 tumor protein p53 Homo sapiens 14-17 15116093-4 2004 Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 60-67 tumor protein p53 Homo sapiens 106-109 15116093-4 2004 Pretreatment of MCF7 cells with an ERK2 chemical inhibitor, PD98059 or U0126, blocked doxorubicin-induced p53 activation and suppressed phosphorylation of p53Thr55. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 60-67 tumor protein p53 Homo sapiens 155-158 15212949-3 2004 Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 60-67 tumor protein p53 Homo sapiens 128-131 15212949-3 2004 Decreasing phospho-ERK with the pharmacological inhibitors, PD98059 and U0126, markedly suppresses hyperoxia-stimulated phospho-p53(Ser15), p53, and p21(CIP1), and also restores the hyperoxia-reduced kinase activities of cyclin D1/E1-Cdks. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 60-67 tumor protein p53 Homo sapiens 140-143 11245472-5 2001 Stable expression of a dominant negative mutant of ERK2 or p38 kinase or their respective inhibitor, PD98059 or SB202190, repressed the phosphorylation of p53 at serine 15. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 101-108 tumor protein p53 Homo sapiens 155-158 12065679-8 2002 Furthermore, treatment with PD98059 significantly decreased the level of p21 protein, a p53-dependent gene product. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 28-35 tumor protein p53 Homo sapiens 88-91 12439598-8 2002 Treatment of cells with PD98059 or UO126 after cisplatin incubation or inhibition of signaling through ERK by tetracycline-regulated expression of dominant-inhibitory ERK enhanced resistance to cisplatin in p53-negative osteosarcoma cells and reduced cisplatin-induced apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 24-31 tumor protein p53 Homo sapiens 207-210 12065679-7 2002 In these studies using mitogen-activated protein kinase inhibitors, infection-induced increases in the p53 level were partially blocked by PD98059, a synthetic inhibitor of MEK1 that is the immediate upstream kinase of extracellular signal-regulated kinases 1/2 (ERK1/2), but not by SB202190, a potent p38 kinase inhibitor. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 139-146 tumor protein p53 Homo sapiens 103-106 11314025-6 2001 Pre-treatment of cells with the specific MEK1 inhibitor PD098059 also attenuated colcemid-induced p53 activation and G1 cell cycle arrest. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 56-64 tumor protein p53 Homo sapiens 98-101 11245472-9 2001 Furthermore, pretreatment of the cells with PD98059 or SB202190 or stable expression of a dominant negative mutant of ERK2 or p38 kinase impaired resveratrol-induced p53-dependent transcriptional activity and apoptosis, whereas constitutively active MEK1 increased the transcriptional activity of p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 44-51 tumor protein p53 Homo sapiens 166-169 11245472-9 2001 Furthermore, pretreatment of the cells with PD98059 or SB202190 or stable expression of a dominant negative mutant of ERK2 or p38 kinase impaired resveratrol-induced p53-dependent transcriptional activity and apoptosis, whereas constitutively active MEK1 increased the transcriptional activity of p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 44-51 tumor protein p53 Homo sapiens 297-300 10050883-4 1999 In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 170-177 tumor protein p53 Homo sapiens 98-101 10547071-9 1999 The effect of OM on p53 expression seems to be mediated through the extracellular signal-regulated kinase (ERK) pathway, inasmuch as the inhibition of ERK activation with a specific inhibitor (PD98059) to the ERK upstream kinase mitogen/extracellular-regulated protein kinase kinase abrogated the OM inhibitory activity on p53 expression in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 193-200 tumor protein p53 Homo sapiens 20-23 10547071-9 1999 The effect of OM on p53 expression seems to be mediated through the extracellular signal-regulated kinase (ERK) pathway, inasmuch as the inhibition of ERK activation with a specific inhibitor (PD98059) to the ERK upstream kinase mitogen/extracellular-regulated protein kinase kinase abrogated the OM inhibitory activity on p53 expression in a dose-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 193-200 tumor protein p53 Homo sapiens 323-326 10050883-4 1999 In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 170-177 tumor protein p53 Homo sapiens 239-242 10050883-4 1999 In an effort to identify potential signaling cascades through which Tpo illicits these effects on p53, we report here that treating M07e cells with MAPK kinase inhibitor PD98059 dramatically suppressed Tpo-induced conformational change in p53 as well as Tpo-enhanced viability in M07e cells in a p53-dependent manner. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 170-177 tumor protein p53 Homo sapiens 239-242 9588214-6 1998 As expected, PD98059 inhibited induction of p53 mRNA and p21WAF1/CIP1 promoter by IGF I. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 13-20 tumor protein p53 Homo sapiens 44-47 28785074-7 2017 In addition, treatment of PD98059 reversed low-dose arsenite-induced MDM2 expression, and the inhibition of ERK2 expression could significantly block MDM2 expression as a consequence, and p53 expression automatically was increased. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 26-33 tumor protein p53 Homo sapiens 188-191 22466960-8 2012 Interruption of ERK and p53 activities decreased SU11274-induced autophagy, and blocking of ERK by the specific inhibitor PD98059 suppressed SU11274-induced p53 activation. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 122-129 tumor protein p53 Homo sapiens 157-160 21261644-5 2011 By a PD98059-inhibitable process, resveratrol causes inducible COX-2 to accumulate in the nucleus where it complexes with pERK1/2 and p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 5-12 tumor protein p53 Homo sapiens 134-137 20564491-6 2010 Moreover, inhibition of ERK by treatment of cells with the ERK-specific inhibitor PD98059 blocked WEGS-mediated p53 expression. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 82-89 tumor protein p53 Homo sapiens 112-115 29405768-5 2018 The MEK inhibitor PD98059 and ERK1/2 siRNA significantly inhibited apoptosis, ERK1/2 activation, as well as p53 and phospho-p53 (serine-15) levels in human lymphoblasts undergoing DEB-induced apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 tumor protein p53 Homo sapiens 108-111 29405768-5 2018 The MEK inhibitor PD98059 and ERK1/2 siRNA significantly inhibited apoptosis, ERK1/2 activation, as well as p53 and phospho-p53 (serine-15) levels in human lymphoblasts undergoing DEB-induced apoptosis. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 tumor protein p53 Homo sapiens 124-127 28833404-7 2018 The ERK inhibitor PD98059 and siRNA-mediated ERK silencing induced G1 arrest and p21WAF1/CIP1 expression by downregulating c-Myc in p53-deficient cells. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 18-25 tumor protein p53 Homo sapiens 132-135 28287251-9 2018 Inhibition of ERK1/2 using PD98059, a selective MEK inhibitor, blocked the apoptotic cell death but prevented CDDP-induced accumulation of p53 and PUMA. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 27-34 tumor protein p53 Homo sapiens 139-142 26497030-5 2016 Interestingly, an increase in phosphorylation of p53 was paralleled with p-Erk, and PD98059 also blocked the level of p-p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 84-91 tumor protein p53 Homo sapiens 49-52 26497030-5 2016 Interestingly, an increase in phosphorylation of p53 was paralleled with p-Erk, and PD98059 also blocked the level of p-p53. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 84-91 tumor protein p53 Homo sapiens 120-123 26497030-8 2016 Moreover, PD98059 significantly decreased the levels of p-Erk and p-p53; however, p53 siRNA had little effect on the level of p-Erk. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 10-17 tumor protein p53 Homo sapiens 68-71 26386653-7 2015 We also found that under serum deprivation condition, leptin decreases p53 levels and the inhibitory leptin effect is lost when cells were pretreated with 50 muM PD98059 or 10 muM LY29004; or were transfected with dominant negative mutants of intermediates of these pathways, suggesting that MAPK and PI3K signaling pathways are necessaries for leptin action. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 162-169 tumor protein p53 Homo sapiens 71-74 21311676-8 2010 With the co-treatment of PD98059 and melatonin, the expression of p-p53, p21, and MDM2 did not decrease. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 25-32 tumor protein p53 Homo sapiens 68-71 20036733-7 2010 UVB-irradiated KP provoked an appreciable accumulation of pSer(15)-p53/COX-2 complexes, but this nuclear association of complexes was partially inhibited by PD98059. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 157-164 tumor protein p53 Homo sapiens 67-70